Fig. 4

Differences in Δ plasma p-tau217 across the diagnostic groups, cohort 2 only. The groups were stratified according to amyloid status determined by the Aβ42/Aβ40 ratio and by clinical diagnosis at follow-up (e.g., MCI-AD Aβ+ has AD dementia at follow-up). Brackets indicate a significant difference between the groups, determined by general linear models with post hoc LSD tests, adjusted for age, sex, and total follow-up time. Plasma p-tau217 levels were z-scored to facilitate comparison between plasma p-tau217+_Janssen and plasma p-tau217_Lilly assays. AUC, area under the curve